Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Metrics to compare | LDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLDXPeersSector | |
---|---|---|---|---|
P/E Ratio | −10.8x | −4.1x | −0.7x | |
PEG Ratio | −0.27 | −0.18 | 0.00 | |
Price/Book | 12.6x | 3.7x | 2.6x | |
Price / LTM Sales | 6.3x | 3.1x | 3.4x | |
Upside (Analyst Target) | −37.5% | 28.8% | 36.2% | |
Fair Value Upside | Unlock | 0.4% | 4.1% | Unlock |